Surrozen, Inc/de

Surrozen, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Surrozen announced its first quarter 2026 financial results, reporting $5 million in collaboration revenue and maintaining a strong cash position of $106.9 million, while advancing its SZN-8141 IND submission.

Surrozen, Inc. announced its full-year 2025 financial results, highlighted by pipeline advancements, a $5 million milestone payment from Boehringer Ingelheim, and a significant increase in net loss.

Dr. Shao-Lee Lin has resigned from Surrozen, Inc.'s Board of Directors, effective January 26, 2026, with no reported disagreements.

Surrozen, Inc. announced Andrew Maleki as its new CFO and reported a significant net loss of $71.6 million for Q3 2025, alongside progress in its ophthalmology pipeline.

Surrozen, Inc. announced the termination of its collaboration agreement with TCGFB, Inc., effective November 13, 2025, without penalties.

Surrozen, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $127.5 million and continued investment in its Wnt pathway-modulating therapeutics for ophthalmic diseases.

Surrozen, Inc. reported a significant net loss of $71.6 million for Q3 2025, driven by non-cash charges and increased R&D for its ophthalmology pipeline, while discontinuing its SZN-043 program and facing termination of a key research collaboration.

Surrozen, Inc. reported a net income of $39.7 million for Q2 2025, driven by non-cash gains from warrant and tranche liability fair value adjustments, and secured significant funding for its ophthalmology pipeline.

Surrozen Inc. announces its financial results for the first quarter of 2025, focusing on the progress of its ophthalmology programs and recent financing activities.

Surrozen Inc. announced its Q3 2024 financial results, including a $10 million milestone payment from Boehringer Ingelheim and a net loss of $1.4 million.

Surrozen, Inc. released its second quarter 2024 results, detailing financial performance and progress in clinical development, including the initiation of a Phase 1b trial for SZN-043.

Surrozen, Inc. reported a significant increase in net losses for 2025, driven by non-cash charges and increased R&D, while advancing its Wnt-pathway ophthalmology pipeline and securing new financing.

Surrozen, Inc.'s 10-K filing reveals a year of strategic shifts, pipeline advancements, and financial recalibration as the company focuses on ophthalmology and navigates ongoing losses.

Surrozen Inc.'s 10-K filing details the company's financial status, clinical trial progress, and strategic focus on Wnt pathway modulation for tissue repair.

TCG Crossover GP II, LLC and 4 others reported changes in beneficial ownership of Surrozen, Inc./DE common stock on July 22, 2026.

Surrozen, Inc. Chief Financial Officer Andrew Pedrum Maleki acquired 607 shares of common stock through the company's Employee Stock Purchase Plan.

Executive Vice President of Research Li Yang acquired 1,666 shares of Surrozen, Inc. common stock via the employee stock purchase plan.

Chief Operating Officer Charles Williams acquired 1,666 shares of Surrozen, Inc. common stock through the company's Employee Stock Purchase Plan.

Tim Kutzkey, a Director and 10% Owner of Surrozen, Inc., reported the acquisition of stock options.

Mace Rothenberg, a Director at Surrozen, Inc., acquired 5,550 stock options with an exercise price of $30.14 on May 13, 2026.

Surrozen, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on May 13, 2026, to vote on director elections, auditor ratification, and executive compensation, while disclosing a significant increase in net losses.

Surrozen, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) in compliance with Section 14(a) of the Securities Exchange Act of 1934.

Surrozen, Inc. announces its 2025 annual meeting of stockholders to be held virtually on May 14, 2025, featuring proposals for director elections and ratification of the company's independent accounting firm.

Surrozen, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) in compliance with Section 14(a) of the Securities Exchange Act of 1934.

Surrozen, Inc. will hold its 2024 annual meeting of stockholders virtually on June 5, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent registered public accounting firm.

The Column Group entities and individuals have updated their beneficial ownership filings for Surrozen, Inc., reflecting changes in their holdings and the overall share count.

The Column Group and its affiliates, including managing partners Tim Kutzkey and Peter Svennilson, have significantly increased their beneficial ownership in Surrozen, Inc. to 35.1% through recent stock purchases.

The Column Group entities and their managing partners have significantly increased their beneficial ownership in Surrozen, Inc. to up to 34% through a two-tranche private placement and a repricing of existing warrants, signaling continued investment and strategic alignment.

TCG Crossover entities and Chen Yu have updated their Schedule 13G filing, reporting a combined beneficial ownership of 9.9% in Surrozen, Inc.

Venrock Healthcare Capital Partners and affiliates have filed a Schedule 13G/A reporting a 9.99% beneficial ownership stake in Surrozen, Inc. as of March 31, 2026.

5AM Ventures VII, L.P. and its affiliates report a 9.5% beneficial ownership stake in Surrozen, Inc. common stock.

Boxer Capital Management and associated entities have filed a Schedule 13G reporting a 6.67% beneficial ownership stake in Surrozen, Inc.

StemPoint Capital LP, along with affiliated entities and individuals, has reported a beneficial ownership of 4.5% in Surrozen, Inc. common stock.

Point72 Asset Management and Steven A. Cohen have reported a 5.4% beneficial ownership stake in Surrozen, Inc. common stock.